Division of Child and Adolescent Psychiatry, Stony Brook University School of Medicine, Stony Brook, NY 11794-8790, USA.
Bipolar Disord. 2010 Mar;12(2):205-12. doi: 10.1111/j.1399-5618.2010.00793.x.
OBJECTIVE: To examine the safety and efficacy of liquid risperidone to reduce duration of rages in children with severe mood dysregulation (SMD) or possible bipolar disorder (BP). METHOD: The sample included 151 consecutive admissions of 5-12 year old children to a psychiatric inpatient unit. Diagnostic information and history of prior rage outbursts were obtained at admission. In hospital, a first rage was treated with seclusion. If a second rage occurred, the child was offered liquid risperidone to help him/her regain control. Durations of unmedicated and last medicated rage were compared. Rage frequency in children with SMD and several definitions of BP were compared. RESULTS: Although 82 of 151 admissions were prompted by rages, rages occurred during only 49 hospitalizations and occurred more than once in only 24. In 16 multiply medicated children, duration of rages dropped from a baseline of 44.4 +/- 20.2 min to 25.6 +/- 12.5 min at the child's last dose. Neither SMD nor any definition of BP influenced rage response in this small sample. The average liquid risperidone dose was 0.02 mg/kg. All but two children also took atypical antipsychotics daily. In the evaluation of medicated rage episodes with standard rating scales, no extrapyramidal side effects, akathisia, or abnormal involuntary movements were observed, and the rate of sedation/sleepiness (7/67 = 10.4%) was similar and not significantly different from that observed during nonmedicated episodes (8/46 = 17.4%). CONCLUSIONS: Liquid risperidone may be a safe and effective way to shorten the duration of rage episodes regardless of diagnosis. However, definitive conclusions cannot be drawn in the absence of a placebo control as children were also receiving other behavioral and psychopharmacologic treatments.
目的:研究液体利培酮降低严重情绪失调(SMD)或可能双相障碍(BP)儿童发怒持续时间的安全性和有效性。
方法:该样本包括 151 名连续入住精神病住院病房的 5-12 岁儿童。入院时获得诊断信息和既往发怒发作史。住院期间,首次发怒发作时采用隔离。如果发生第二次发怒,将向患儿提供液体利培酮以帮助其恢复控制。比较无药物治疗和最后药物治疗发怒的持续时间。比较 SMD 儿童和几种 BP 定义的发怒频率。
结果:尽管 151 次入院中有 82 次是由发怒引起的,但仅在 49 次住院期间发生了发怒,并且仅在 24 次住院期间发生了多次发怒。在 16 名多次用药的儿童中,发怒的持续时间从基线的 44.4±20.2 分钟降至最后一剂的 25.6±12.5 分钟。在这个小样本中,无论是 SMD 还是任何 BP 定义都没有影响发怒反应。平均液体利培酮剂量为 0.02mg/kg。除两名儿童外,所有儿童还每天服用非典型抗精神病药。在使用标准评定量表评估有药物治疗的发怒发作时,未观察到锥体外系副作用、静坐不能或异常不自主运动,镇静/嗜睡发生率(7/67=10.4%)与无药物治疗发作时相似,且无统计学差异(8/46=17.4%)。
结论:液体利培酮可能是一种安全有效的缩短发怒发作持续时间的方法,无论诊断如何。然而,由于儿童还接受其他行为和精神药理学治疗,因此在没有安慰剂对照的情况下,无法得出明确的结论。
J Child Adolesc Psychopharmacol. 2009-6
Encephale. 2004
JAACAP Open. 2024-1-19
Res Child Adolesc Psychopathol. 2024-6
BMJ Open. 2019-12-23
Evid Based Ment Health. 2018-10-25
J Can Acad Child Adolesc Psychiatry. 2015
J Child Adolesc Psychopharmacol. 2013-5
Am J Psychiatry. 2010-12-1
J Child Adolesc Psychopharmacol. 2009-6
J Child Adolesc Psychopharmacol. 2009-2
Am J Psychiatry. 2009-1
J Child Adolesc Psychopharmacol. 2007-8
J Am Acad Child Adolesc Psychiatry. 2007-7
J Am Acad Child Adolesc Psychiatry. 2007-3
J Am Acad Child Adolesc Psychiatry. 2007-1
Arch Gen Psychiatry. 2006-2